Molina Healthcare's fundamentals appear to be deteriorating across all three statements: revenue growth has swung from +21.0% in 2024Q3 to -7.8% in 2026Q3 across four consecutive negative quarters, while the combined ratio widened to 99.0%, leaving only a 1.0% underwriting margin and pushing quarterly net income down…
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue contracted 7.8% year-over-year to $10.6B in 2026Q3 while the loss ratio rose to 91.8% and the combined ratio reached 99.0%, implying only a 7.2% expense ratio has prevented an outright underwriting loss.
Mohawk is the largest flooring company globally, offering a comprehensive range of hard and soft surface products. Its vertically integrated manufacturing and distribution processes provide a competitive advantage, allowing for control over production from raw materials to finished goods.
Despite recent revenue and net income decreases, analysts project earnings growth for Mohawk Industries. Earnings are expected to rise by approximately 14.65% in the coming year, with EPS projected to increase significantly by 2029.
Some analyses suggest MHK is undervalued, with a narrative fair value around $126.53, implying about 16% undervaluation. Its P/E ratio is also noted as being less expensive than the market average.
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 21, 2026 | $0.89+12.7% vs $0.79 | $11.1B+2.1% vs $10.9B |
Q3 2026 Jul 22, 2026 | $1.51+8.6% vs $1.39 | $10.9B+0.4% vs $10.8B |
Q2 2026 Apr 22, 2026 | $2.35+23.7% vs $1.90 | $10.8B-0.7% vs $10.9B |
Q1 2026 Feb 5, 2026 | -$2.75-739.5% vs $0.43 | $11.4B+4.6% vs $10.9B |
Molina Healthcare NYSE: MOH reaffirmed its full-year 2026 adjusted earnings outlook while outlining preliminary 2027 earnings building blocks exceeding $9.50 per share, supported by anticipated rate increases, the maturation of new contracts and the planned exit from its Medicare Advantage prescription drug business.
Molina Healthcare, Inc. ( MOH ) Q3 2026 Earnings Call October 22, 2026 8:00 AM EDT Company Participants Jeffrey Geyer - Head of Investor Relations Joseph Zubretsky - President, CEO & Director Mark Keim - Senior EVP, CFO & Treasurer Conference Call Participants Andrew Mok - Barclays Bank PLC, Research Division Kevin Fischbeck - BofA Securities, Research Division John Stansel - JPMorgan Chase & Co, Research Division Justin Lake - Wolfe Research, LLC Albert Rice - UBS Investment Bank, Research Division Stephen Baxter - Wells Fargo Securities, LLC, Research Division Scott Fidel - Goldman Sachs Group, Inc., Research Division Sarah James - Cantor Fitzgerald & Co., Research Division David Windley - Jefferies LLC, Research Division Ryan Langston - TD Cowen, Research Division Lance Wilkes - Bernstein Institutional Services LLC, Research Division Michael Ha George Hill - Deutsche Bank AG, Research Division Presentation Operator Good day, and welcome to the Molina Healthcare Third Quarter 2026 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded.
Molina (MOH) came out with quarterly earnings of $0.89 per share, beating the Zacks Consensus Estimate of $0.72 per share. This compares to earnings of $1.84 per share a year ago.
While the top- and bottom-line numbers for Molina (MOH) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Benchmark MOH against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Molina Healthcare, Inc. (MOH)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $208.99 | $10.91B | 23.43 | 11.75% | 1.04% | 11.02% | — | |
| $69.70 | $34.43B | -5.12 | 19.44% | 0.75% | 6.76% | — | |
| $7.34 | $1.52B | -1983.78 | 46.06% | 0.59% | 12.46% | — | |
| $394.15 | $357.95B | 29.79 | 11.81% | 3.53% | 15.18% | 2.21% | |
| $83.85 | $106.99B | 60.32 | 7.85% | 1.18% | 6.41% | 3.19% | |
| $425.62 | $92.3B | 16.94 | 12.62% | 2.55% | 11.56% | 1.62% |
Molina Healthcare, Inc. (MOH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Molina Healthcare, Inc. (MOH) SEC filings — annual & quarterly reports (10-K, 10-Q)
Oct 21, 2026·SEC
Jul 22, 2026·SEC
Jun 10, 2026·SEC
Get notified when MOH posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Molina Healthcare, Inc. (MOH) stock FAQ — growth, dividends, profitability & financials explained
Molina Healthcare, Inc. (MOH) grew revenue by 11.7% in fiscal year 2025, compared with the prior fiscal year.
No. Molina Healthcare, Inc. (MOH) reported a net loss of $48.0M over the trailing twelve months.
Molina Healthcare, Inc. (MOH) had a return on equity (ROE) of 11.0% in fiscal year 2025. That is in line with the market's typical 10-15%.
Molina Healthcare, Inc. (MOH) has a combined ratio of 98.3%. A ratio below 100% indicates underwriting profitability.
